| Compound Information | SONAR Target prediction |
| Name: | Felbamate |
| Unique Identifier: | LOPAC 00351 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | C11H14N2O4 |
| Molecular Weight: | 224.129 g/mol |
| X log p: | 10.703 (online calculus) |
| Lipinksi Failures | 1 |
| TPSA | 52.6 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 6 |
| Rotatable Bond Count: | 7 |
| Canonical Smiles: | NC(=O)OCC(COC(N)=O)c1ccccc1 |
| Class: | Glutamate |
| Action: | Antagonist |
| Generic_name: | Felbamate |
| Chemical_iupac_name: | trideca-1,3,11-trien-5,7,9-triyne |
| Drug_type: | Approved Drug |
| Pharmgkb_id: | PA449590 |
| Kegg_compound_id: | C07501 |
| Drugbank_id: | APRD00505 |
| Melting_point: | 151.5 oC |
| H2o_solubility: | Slightly soluble in water |
| Logp: | 0.76 |
| Cas_registry_number: | 25451-15-4 |
| Drug_category: | Antiepileptic Agents; Anticonvulsants; Neuroprotective Agents; ATC:N03AX10 |
| Indication: | For use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. |
| Pharmacology: | Felbamate is an antiepileptic indicated as monotherapy or as an adjunct to other anticonvulsants for the treatment of partial seizures resulting from epilepsy. Receptor-binding studies in vitro indicate that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding, and is devoid of activity at the MK-801 receptor binding site of the NMDA receptor-ionophore complex. However, felbamate does interact as an antagonist at the strychnine-insensitive glycine recognition site of the NMDA receptor-ionophore complex. |
| Mechanism_of_action: | The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. In vitro receptor binding studies suggest that felbamate may be an antagonist at the strychnine-insensitive glycine-recognition site of the N-methyl-D-aspartate (NMDA) receptor-ionophore complex. Antagonism of the NMDA receptor glycine binding site may block the effects of the excitatory amino acids and suppress seizure activity. Animal studies indicate that felbamate may increase the seizure threshold and may decrease seizure spread. |
| Organisms_affected: | Humans and other mammals |
| Found: 24 nonactive as graph: single | with analogs | 1 2 3 4 5 6 7 8 9 10 Next >> [24] |
| Species: | 4932 |
| Condition: | BY4741 |
| Replicates: | 8 |
| Raw OD Value: r im | 0.8442±0.108074 |
| Normalized OD Score: sc h | 1.0194±0.0140398 |
| Z-Score: | 0.8238±0.523065 |
| p-Value: | 0.410068 |
| Z-Factor: | -4.12851 |
| Fitness Defect: | 0.8914 |
| Bioactivity Statement: | Nonactive |
| ps |
| DBLink | Rows returned: 2 |
| 3331 | (3-carbamoyloxy-2-phenyl-propyl) carbamate |
| 89605 | (3-carbamoyloxy-2-methyl-2-phenyl-propyl) carbamate |
| internal high similarity DBLink | Rows returned: 0 |
| active | Cluster 6099 | Additional Members: 2 | Rows returned: 0 |
Service provided by the
Mike Tyers Laboratory